Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:CRDF

Cardiff Oncology Q3 2026 Earnings Date & Estimates

Cardiff Oncology logo
$0.80 -0.10 (-11.35%)
Closing price 04:00 PM Eastern
Extended Trading
$0.82 +0.02 (+2.45%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiff Oncology is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cardiff Oncology in Q3 2026

Cardiff Oncology is expected to post earnings of -$0.14 per share on revenue of $81 thousand. In the same quarter a year earlier Cardiff Oncology reported -$0.17 per share on revenue of $120 thousand. Cardiff Oncology last reported on August 11, 2026, posting -$0.14 per share and missing the -$0.1196 consensus estimate. Cardiff Oncology has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.14
Expected Revenue
$81 thousand
Prior-Year EPS
-$0.17
Prior-Year Revenue
$120 thousand
Expected Revenue Growth
-32.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.14 (Missed by -$0.0204)
Last Quarter Revenue
$104 thousand
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Cardiff Oncology Q3 2026 Earnings FAQ

Cardiff Oncology (NASDAQ:CRDF) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Cardiff Oncology's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cardiff Oncology to post earnings of -$0.14 per share for Q3 2026.

The consensus revenue estimate for Cardiff Oncology is $81 thousand for Q3 2026.

Cardiff Oncology Earnings Headlines

Cardiff Oncology (NASDAQ:CRDF) & Xencor (NASDAQ:XNCR) Head to Head Contrast
October 25 at 4:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31155524
Cardiff's Onvansertib Wins FDA Orphan Drug Designation For Rare Blood Cancer
October 23 at 8:19 AM  |  rttnews.comhttps://www.rttnews.com/3702358/cardiff-s-onvansertib-wins-fda-orphan-drug-designation-for-rare-blood-cancer.aspx
My Deep Cut Pick Before Anthropic's IPO
The biggest IPO in history is likely just weeks away... at a valuation of up to $2 trillion Anthropic could make the SpaceX listing look tiny. But here's what nobody's talking about... A raise of about $100 billion doesn't just sit still. When a listing this size breaks, the money moves. And the fastest-moving corner of that flow has always been crypto. I've called this kind of setup before. KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. ALBT: 1,933%. All went to our community before the big move.tc pixel
October 26 at 1:00 AM  |  Crypto 101 Media (Ad)
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
October 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385898/0/en/cardiff-oncology-receives-fda-orphan-drug-designation-for-onvansertib-in-chronic-myelomonocytic-leukemia.html
Nektar Therapeutics (NASDAQ:NKTR) vs. Cardiff Oncology (NASDAQ:CRDF) Head to Head Survey
October 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31133973
Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock Has Consensus Price Target of $7.50 According to Analysts
October 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31130172
See More Cardiff Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email.

About Cardiff Oncology

Cardiff Oncology (NASDAQ:CRDF) is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead product candidate is onvansertib, an oral, selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cancer-cell division.

Cardiff Oncology has primarily evaluated onvansertib in combination with standard treatments for patients with RAS-mutated metastatic colorectal cancer, including investigations involving KRAS-mutated disease. The company has also explored the candidate in other solid tumors, including metastatic castration-resistant prostate cancer. Onvansertib is an investigational therapy and has not been approved for commercial use.

The company was formerly known as Trovagene, Inc. and adopted the Cardiff Oncology name in 2020 to reflect its focus on oncology drug development. Based in San Diego, California, Cardiff Oncology conducts its research and clinical-development activities primarily through studies in the United States. Mark Erlander has served as the company’s chief executive officer and is a physician-scientist with experience in oncology drug development.

View Cardiff Oncology Profile
Earnings Tools